Registered title, quoted from ClinicalTrials.gov
A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page
- Study siteShanghai Pulmonary Hospital上海市肺科医院ShanghaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07642024, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
ECOG performance status score of 0 or 1;
Inclusion criterion 8
Diagnosis of active malignant tumors within 5 years prior to study randomization;
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07642024, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign informed consent and agree to comply with the protocol requirements;
- Aged ≥18 years and ≤75 years, regardless of gender;
- Expected survival time ≥3 months;
- Patients with non-small cell lung cancer;
- One of the EGFR sensitive mutation types detected in the tumor tissue;
- Agree to provide archived primary tumor tissue specimens obtained within 12 months or fresh tissue samples;
- Undergo pulmonary function testing within 28 days prior to the first dose;
- ECOG performance status score of 0 or 1;
- No severe cardiac dysfunction;
- Organ function levels must meet the required criteria;
- Urine protein ≤1+ or <1000 mg/24h;
- For premenopausal women of childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, and the serum pregnancy test must exclude pregnancy; patients must not be lactating; all enrolled trial participants must use adequate barrier contraceptive measures throughout the entire treatment period and for 7 months after the end of treatment.
Exclusion Criteria:
- SCLC, mixed SCLC and NSCLC, or other non-NSCLC pathological types;
- Trial participants who subsequently receive only segmentectomy or wedge resection;
- Trial participants deemed surgically inoperable by the study center's surgical evaluation;
- Undergoing major surgery within 4 weeks prior to the first dose, among others;
- Previous receipt of systemic anti-tumor therapy for non-small cell lung cancer other than that for this study, among others;
- Receiving long-term systemic corticosteroid therapy with prednisone >10 mg/day within 2 weeks prior to randomization, among others;
- History of severe heart disease or cerebrovascular disease;
- Prolonged QTc interval, complete left bundle branch block, etc.;
- Any thrombotic event within 6 months prior to screening;
- Trial participants with known or suspected interstitial lung disease, among others;
- Diagnosis of active malignant tumors within 5 years prior to study randomization;
- Hypertension inadequately controlled by two antihypertensive medications;
- Trial participants with poorly controlled blood glucose;
- Severe infection occurring within 4 weeks prior to study randomization, among others;
- Presence of large serous cavity effusion, or serous cavity effusion with symptoms, etc.;
- Imaging findings indicating tumor invasion or encasement of the abdomen, chest, etc.;
- Severe non-healing wounds, ulcers, or fractures within 4 weeks prior to signing informed consent;
- Trial participants with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent;
- Inflammatory bowel disease, history of extensive bowel resection, history of immune-related enteritis, etc.;
- History of allergy to the investigational drug, etc.;
- History of solid organ transplantation, autologous or allogeneic stem cell transplantation;
- Positive for human immunodeficiency virus antibodies, active hepatitis B virus infection, or hepatitis C virus infection;
- History of severe neurological or psychiatric disorders;
- Trial participants planning to receive or having received live vaccines within 28 days prior to study randomization;
- Other conditions deemed by the investigator as unsuitable for participation in this clinical trial due to complications or other circumstances.
Quoted from ClinicalTrials.gov, NCT07642024, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07642024, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.